GNI Group Ltd
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical tri… Read more
GNI Group Ltd (3G6) - Total Liabilities
Latest total liabilities as of June 2025: €29.41 Billion EUR
Based on the latest financial reports, GNI Group Ltd (3G6) has total liabilities worth €29.41 Billion EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GNI Group Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how GNI Group Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GNI Group Ltd Competitors by Total Liabilities
The table below lists competitors of GNI Group Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cleanaway Co Ltd
TW:8422
|
Taiwan | NT$12.77 Billion |
|
Ennoconn Corp
TW:6414
|
Taiwan | NT$96.97 Billion |
|
Korian S.A.
LSE:0OPS
|
UK | €11.24 Billion |
|
Parksystems Corp
KQ:140860
|
Korea | ₩104.85 Billion |
|
Firstsource Solutions Limited
NSE:FSL
|
India | ₹42.95 Billion |
|
Wuxi Huadong Heavy Machinery Co Ltd
SHE:002685
|
China | CN¥1.13 Billion |
|
Capitol Federal Financial Inc
NASDAQ:CFFN
|
USA | $8.74 Billion |
|
TRTPF
PINK:TRTPF
|
USA | $117.35 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down GNI Group Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GNI Group Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GNI Group Ltd (2013–2024)
The table below shows the annual total liabilities of GNI Group Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €32.23 Billion | +22.35% |
| 2023-12-31 | €26.34 Billion | +86.87% |
| 2022-12-31 | €14.10 Billion | +27.79% |
| 2021-12-31 | €11.03 Billion | +5.56% |
| 2020-12-31 | €10.45 Billion | +39.12% |
| 2019-12-31 | €7.51 Billion | +107.95% |
| 2018-12-31 | €3.61 Billion | +50.66% |
| 2017-12-31 | €2.40 Billion | +86.47% |
| 2016-12-31 | €1.29 Billion | +2.20% |
| 2015-12-31 | €1.26 Billion | +28.63% |
| 2014-12-31 | €978.00 Million | +25.55% |
| 2013-12-31 | €779.00 Million | -- |